Kostas Biliouris
Stock Analyst at Oppenheimer
(1.17)
# 3,785
Out of 5,122 analysts
64
Total ratings
37.25%
Success rate
-15.34%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kostas Biliouris
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KRRO Korro Bio | Upgrades: Outperform | $22 | $12.26 | +79.45% | 4 | Jan 28, 2026 | |
| CNTA Centessa Pharmaceuticals | Maintains: Outperform | $40 → $62 | $25.00 | +148.00% | 7 | Dec 10, 2025 | |
| SRPT Sarepta Therapeutics | Upgrades: Outperform | $50 | $19.73 | +153.42% | 9 | Sep 22, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Outperform | $450 → $470 | $351.96 | +33.54% | 6 | Sep 8, 2025 | |
| IONS Ionis Pharmaceuticals | Upgrades: Outperform | $40 → $70 | $84.99 | -17.64% | 3 | Sep 3, 2025 | |
| JSPR Jasper Therapeutics | Downgrades: Market Perform | $15 → $4 | $1.38 | +189.86% | 1 | Jul 8, 2025 | |
| RCKT Rocket Pharmaceuticals | Maintains: Outperform | $30 → $8 | $3.33 | +140.24% | 2 | May 28, 2025 | |
| RNA Avidity Biosciences | Initiates: Outperform | $72 | $72.72 | -0.99% | 1 | Mar 12, 2025 | |
| DYN Dyne Therapeutics | Initiates: Outperform | $50 | $18.23 | +174.27% | 1 | Mar 12, 2025 | |
| SLN Silence Therapeutics | Maintains: Outperform | $67 → $25 | $4.30 | +481.40% | 2 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $70 → $50 | $12.36 | +304.53% | 6 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $34 | $3.83 | +787.73% | 3 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $22 → $17 | $1.45 | +1,072.41% | 2 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $63 → $40 | $9.29 | +330.57% | 4 | Jul 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $90 | $16.65 | +440.54% | 3 | Jul 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $57 | $26.95 | +111.50% | 3 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $37 | $75.19 | -50.79% | 1 | Jan 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $102 → $100 | $57.62 | +73.55% | 4 | Nov 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $19 | $3.48 | +446.76% | 1 | Oct 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $98 | $50.17 | +95.34% | 1 | Jun 17, 2022 |
Korro Bio
Jan 28, 2026
Upgrades: Outperform
Price Target: $22
Current: $12.26
Upside: +79.45%
Centessa Pharmaceuticals
Dec 10, 2025
Maintains: Outperform
Price Target: $40 → $62
Current: $25.00
Upside: +148.00%
Sarepta Therapeutics
Sep 22, 2025
Upgrades: Outperform
Price Target: $50
Current: $19.73
Upside: +153.42%
Alnylam Pharmaceuticals
Sep 8, 2025
Maintains: Outperform
Price Target: $450 → $470
Current: $351.96
Upside: +33.54%
Ionis Pharmaceuticals
Sep 3, 2025
Upgrades: Outperform
Price Target: $40 → $70
Current: $84.99
Upside: -17.64%
Jasper Therapeutics
Jul 8, 2025
Downgrades: Market Perform
Price Target: $15 → $4
Current: $1.38
Upside: +189.86%
Rocket Pharmaceuticals
May 28, 2025
Maintains: Outperform
Price Target: $30 → $8
Current: $3.33
Upside: +140.24%
Avidity Biosciences
Mar 12, 2025
Initiates: Outperform
Price Target: $72
Current: $72.72
Upside: -0.99%
Dyne Therapeutics
Mar 12, 2025
Initiates: Outperform
Price Target: $50
Current: $18.23
Upside: +174.27%
Silence Therapeutics
Mar 4, 2025
Maintains: Outperform
Price Target: $67 → $25
Current: $4.30
Upside: +481.40%
Jan 10, 2025
Maintains: Outperform
Price Target: $70 → $50
Current: $12.36
Upside: +304.53%
Jan 10, 2025
Upgrades: Outperform
Price Target: $34
Current: $3.83
Upside: +787.73%
Aug 15, 2024
Maintains: Outperform
Price Target: $22 → $17
Current: $1.45
Upside: +1,072.41%
Jul 18, 2024
Maintains: Outperform
Price Target: $63 → $40
Current: $9.29
Upside: +330.57%
Jul 3, 2024
Maintains: Outperform
Price Target: $90
Current: $16.65
Upside: +440.54%
Mar 27, 2024
Maintains: Outperform
Price Target: $57
Current: $26.95
Upside: +111.50%
Jan 31, 2024
Initiates: Market Perform
Price Target: $37
Current: $75.19
Upside: -50.79%
Nov 3, 2023
Maintains: Outperform
Price Target: $102 → $100
Current: $57.62
Upside: +73.55%
Oct 9, 2023
Initiates: Outperform
Price Target: $19
Current: $3.48
Upside: +446.76%
Jun 17, 2022
Initiates: Outperform
Price Target: $98
Current: $50.17
Upside: +95.34%